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Abstract. In previous studies we demonstrated telomerase
activity in frozen tissue from head and neck squamous cell
carcinoma (HNSCC) and their tumor-free tumor margins. In
the present study frozen sections from the same tissues were
examined for in situ presence of hTERT. In preliminary
investigations we established that the most suitable method
of tissue preparation was fixation in acetone and methanol
followed by steaming and visualization by APAAP. Most of
the assays involved eleven anti-hTERT antibodies and were
supplemented with the inclusion of antibodies Ki-67, anti-
nucleolin and CD45. hTERT expression was investigated in
the tissues of 61 patients with HNSCC and 37 patients with-
out tumor. Semi-quantitative immunoreactive scores were cor-
related with telomerase activity. We examined the prognostic
significance of hTERT expression with Kaplan-Meier curves
and tested the immunological specificity of the antibodies by
immunoabsorption with two hTERT peptides and a nucleolin
peptide. Nuclear staining of satisfactory distribution and
intensity was achieved in seven anti-hTERT antibodies both
in the carcinomas and in the squamous epithelia of the tumor
resection margins and in the control tissues. Proof of hTERT
did not differ from telomerase activity. The telomerase activity
demonstrated in tumor-free resection margins and in control
tissues did, however, correlate with lymphocytic-monocytic
infiltration (CD45 expression). This telomerase activity
might be related to nuclear hTERT expression in the
squamous epithelium, given that the hTERT score values in
the connective tissue tended to be negative. The prognostic
significance of hTERT expression demonstrated on paraffin
sections from different tumor localizations was not confirmed
for the frozen sections of patients with HNSCC. The hTERT
specificity of the monoclonal NCL-L-hTERT, whose use as
an antibody against hTERT has been questioned, was re-
examined with immunohistochemical methods, but the
intensity of its immunoabsorption with the nucleolin peptide
did not exceed that observed in the other anti-hTERT anti-
bodies.
Introduction
Squamous cell carcinomas in the head and neck region
(HNSCC) are characterized by a high rate of loco-regional
recurrence and secondary tumors. An important cause of this
is field cancerization (1,2) in the area around the tumor.
In order to identify patients at risk, extensive studies have
examined the specific biology of the invading tumor front
and marginal tissue, and trials are in progress to identify the
molecular or immunohistochemical markers best suited for
characterizing tumor-free margin tissue (3-9).
Telomerase activity was demonstrated in the tumor and in
the tumor margin of head and neck squamous cell carcinomas
(10-12). In earlier studies we looked for a difference in telo-
merase activity between tumor margin tissue of head and
neck tumors, the tumor itself and control tissue (13-15). We
demonstrated telomerase activity in 30% of 20 tumor-free
marginal tissue specimens and in 20 tumor distant tissue
INTERNATIONAL JOURNAL OF ONCOLOGY  34:  1257-1279,  2009
Immunohistochemical determination of the appropriate
anti-hTERT antibodies for in situ detection of telomerase 
activity in frozen sections of head and neck squamous
cell carcinomas and tumor margin tissues
EVA-MARIA FABRICIUS1,  UTE KRUSE-BOITSCHENKO1,  REEM KHOURY1,
GUSTAV-PAUL WILDNER2,  JAN-DIRK RAGUSE1 and MARTIN KLEIN1
1Clinic for Oral and Maxillofacial Surgery, Campus Virchow Hospital and 2formerly Department of Pathology,
Robert-Rössle-Clinic, Campus Berlin-Buch, Charité-Universitätsmedizin, Berlin, Germany
Received January 23, 2009;  Accepted February 23, 2009
DOI: 10.3892/ijo_00000254
_________________________________________
Correspondence to: Dr Eva-Maria Fabricius, Clinic for Oral
and Maxillofacial Surgery, Campus Virchow Hospital, Charité-
Universitätsmedizin, Augustenburger Platz 1, D-13353 Berlin,
Germany
E-mail: eva-maria.fabricius@charite.de
Abbreviations: aa, amino acid; Ab, antibody; APAAP, alkaline
phosphatase anti-alkaline phosphatase; bb, base pairs; EDTA, ethylene
diamine tetraacetic acid; ELISA, enzyme-linked immunosorbent
assay; HNSCC, head and neck squamous cell carcinoma; hTERT,
human telomerase reverse transcriptase; IRS, immunoreactive scores;
MRD, minimal residual disease; PCNA, proliferating cell nuclear
antigen; PCR, polymerase chain reaction; RT-PCR, reverse trans-
criptions-PCR; TA, telomerase activity; TBS, Tris-buffered saline;
TRAP, telomeric repeat amplification protocol; TRS, target retrieval
solution
Key words: head and neck squamous cell carcinoma, tumor margin,
telomerase, human telomerase reverse transcriptase, immunohisto-
chemistry, frozen sections, prognosis
1257-1279  24/3/2009  02:01 ÌÌ  ™ÂÏ›‰·1257
specimens. Proof of telomerase using PCR yields no inform-
ation about telomerase expression in individual cells, but
immunohistochemistry is well suited for the in situ presentation
of telomerase positive cells, providing that suitable antibodies
are available. This prompted us in the present study to subject
the same frozen tissues in which we had demonstrated
telomerase activity by PCR-ELISA [TRAP-protocol, Kim et al
(16)] to an immunohistochemical investigation to find out
specifically which cells express the catalytic protein subunit
of telomerase, human telomerase reverse transcriptase
(hTERT).
When we started, the only immunohistochemical hTERT
results which had been published related to paraffin sections
or cells embedded in paraffin (17-22). The first challenge was
therefore to determine which commercially available antibodies
and which method would yield the best nuclear presentation
of hTERT in frozen sections. At the same time we wanted to
investigate whether proof of hTERT in resection margins was
of prognostic relevance.
After we had completed the experimental phase of our
study, Wu et al (23) reported that the monoclonal antibody
NCL-L-hTERT, which we had considered particularly well
suited to our purposes, reacted primarily to nucleolin. This
prompted us to carry out additional experiments before
interpreting our results and to include the antibodies studied
by Wu et al (23) in our study.
Patients and methods
Patients and tumor tissue samples. All tissues examined were
taken from the head and neck area with previous consent of the
patients in our clinic in the context of diagnostics and therapy.
Ninety-six squamous cell carcinoma specimens (40 tumor
center tissue specimens with carcinoma and possibly squamous
epithelia, 38 tumor-free margin tissues with squamous epithelia
and 18 tumor-free tumor-distant tissues with squamous
epithelia) were collected from 61 patients in the period from
1994 to 1997 (Table I).
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Table I. Characterization of the 61 patients with a head and
neck squamous cell carcinoma (HNSCC).
–––––––––––––––––––––––––––––––––––––––––––––––––
No. Sex/Agea Localization TNM S G
–––––––––––––––––––––––––––––––––––––––––––––––––
1 M/39 Floor of mouth T3N1M0 3 3
2 M/52 Floor of mouth T4N0M0 4a 3
3 M/59 Floor of mouth T1N2M0 4a 2
4 M/50 Floor of mouth T4N1Mx 4a 2
5 M/58 Floor of mouth T3N2M0 4a 3
6 M/62 Floor of mouth T2N2M0 4a 3
7 M/50 Floor of mouth T4N1M0 4a 3
8 M/52 Floor of mouth T4N2cM0 4b 1
9 M/63 Floor of mouth T2N0M0 2 2
10 M/53 Floor of mouth T1N0M0 1 2
11 M/57 Floor of mouth T4N3Mx 4c 3
12 F/65 Floor of mouth tongue T2N0M0 2 2
13 M/55 Floor of mouth  tongue T4N0M0 4a 3
14 M/55 Floor of mouth tongue T4N0Mx 4a 3
15 M/57 Floor of mouth tongue T4N0M0 4a 2
16 M/60 Floor of mouth tongue T4N1M0 4a 3
17 M/49 Floor of mouth tongue T2N0M0 2 2
18 M/46 Floor of mouth tongue T4N0Mx 4a 3
19 M/51 Floor of mouth mandible T2N0M0 2 2
20 M/58 Tongue T2N1M0 3 2
21 M/55 Tonsil, palate T2N1M0 3 3
22 M/81 Tonsil, palate T1N3M0 4b 2
23 M/58 Tonsil, palate T4N3Mx 4b 3
24 M/50 Oral mucosa T2N2bM0 4a 2
25 M/53 Oral mucosa T4NxMx 4a 2
26 M/66 Oral mucosa T1N0M0 1 3
27 M/55 Oral mucosa T1N1M0 3 3
28 M/58 Oral mucosa T4N3M1 4c 2
29 M/59 Oral mucosa T4N2cM0 4a 2
30 F/61 Oral mucosa T4N0M0 4a 2
31 F/76 Buccal mucosa T3N1M0 3 2
32 F/71 Buccal mucosa T3N0M0 3 1
33 M/57 Buccal mucosa T2N1M0 3 2
34 M/75 Lips T2N0M0 2 2
35 F/89 Nose T2N0M0 2 2
36 M/68 Ear T4N0M0 4a 2
37 M/64 Ear T4N0M0 4a 2
38 M/65 Ear T4N1M0 4a 2
39 M/57 Ear T4N1M0 4a 3
40 M/93 Scalp T1N0M0 1 2
41 M/49 Floor of mouth T2N1M0 3 2
42 M/47 Floor of mouth T4N0M0 4a 2
43 M/53 Floor of mouth T1N0M0 1 2
44 M/52 Floor of mouth T1N0M0 1 2
45 M/42 Floor of mouth tongue T4N2cM0 4a 2
46 M/53 Floor of mouth tongue T2N0M0 2 3
47 M/53 Floor of mouth tongue T1N0M0 1 2
48 M/45 Tongue T3N2M0 4a 3
49 F/51 Tongue T3N2M0 4a 3
50 M/50 Tongue T1N0M0 1 3
Table I. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––
No. Sex/Agea Localization TNM S G
–––––––––––––––––––––––––––––––––––––––––––––––––
51 M/52 Tongue TxN0M0 x 1
52 F/64 Tongue T2N2cM0 4a 3
53 M/52 Tonsil, palate T2N2M1 4c 3
54 M/69 Tonsil, palate T4N3Mx 4b 2
55 F/71 Oral mucosa T2N2M0 4a 2
56 F/59 Lips T2N0M0 2 2
57 M/74 Lips T2N0M0 2 2
58 M/66 Lips T1NxMx 1 2
59 F/75 Lips T4NxMx 4a 2
60 M/63 Lips T2N2M0 4a 3
61 M/90 Ear T1N0M0 1 1
–––––––––––––––––––––––––––––––––––––––––––––––––
Sex: M, male; F, female; aAge at tissue harvesting in years; S, staging;
G, grading; x, unknown, see TNM classification (24).
–––––––––––––––––––––––––––––––––––––––––––––––––
1257-1279  24/3/2009  02:01 ÌÌ  ™ÂÏ›‰·1258
The entire frozen section series was examined by a tumor
pathologist with conventional hemalaun-eosin staining to
ensure that carcinoma was present in all tumor center tissue
specimens and that the tumor margins and tumor distant
tissues were all tumor-free.
We examined tissue of different locations from 61 patients
with HNSCC: 51 males (84%) aged 58±11 years and 10 female
patients (16%) aged 68±11 years. Forty-eight patients had oral
and 13 had extraoral squamous cell carcinomas. Patient age
refers to age at the time point of tissue removal. TNM classi-
fication (24) and degree of differentiation were established
by the Institute of Pathology in our hospital. In the tumor center
we evaluated the carcinoma and any squamous epithelium
present. In the tumor-free margin and tumor distant tissues
we evaluated the squamous epithelium.
Patients and control tissue specimens. For a more critical
evaluation of hTERT expression in carcinoma tissues we
examined oral and extraoral control tissue from different
locations in 37 patients without tumor from our clinic in the
period from 1994 to 2004: 20 males aged 36±19 years and
17 females aged 40±20 years. In the control tissue sections
we evaluated hTERT in squamous epithelium. We examined
23 oral (2x palate, 5x gingiva, 9x oral mucosa, 2x oropharynx,
2x cheek and 3x margins of tongue) and 14 extraoral tissues
(1x eye, 2x skin, 1x lips, 3x nose, 4x ear, 2x scalp and 1x
forehead). The tissues were taken with the patients' consent
in the context of therapy.
Antibodies and experiments carried out to optimize frozen
section preparation of squamous cell carcinomas (Table II).
We used the frozen sections from squamous cell carcinomas
in which we had previously demonstrated telomerase activity
in PCR-ELISA (13-15). For optimal immunohistochemical
results we used the four commercially available anti-hTERT
antibodies, the three polyclonal rabbit antibodies [Ab 1, Ab 2
and Ab 4 (Table II)] and one monoclonal murine antibody
[Ab 3 (Table II)]. These were the antibodies used by Hiyama
et al (17), Poremba et al (18-20), Yan et al (21) and Park et al
(22) for paraffin sections and cell cultures embedded in
paraffin to determine hTERT with the EnVision demonstration
system (DakoCytomation, Denmark). Using the same pre-
paratory processing and EnVision we achieved only cyto-
plasmic staining in the squamous cell carcinomas and only in
those epithelial and carcinoma cells with a more or less
stained background. We therefore reverted to APAAP (25-28),
which had proved successful in earlier immunohistochemical
examinations. The purpose was to achieve nuclear and/or
nucleolar presentation of hTERT with commercial antibodies.
Fixation for 9 min in methanol and subsequently 1 min of
aceton fixation at -20˚C proved the most successful method,
more suitable than acetone alone, methanol alone or 4%
paraformaldehyde at 4˚C or -20˚C. Nonetheless, additional
pretreatment of the frozen sections was necessary. The best
nuclear presentation was achieved when the frozen sections
were pretreated for 30 min in a steamer (Braun Multi Gourmet
Plus FS20, Kronberg, Germany) in TRS-Puffer S1699 (Dako
Cytomation) pH 6.1. Results of pretreatment in the autoclave
or microwave in various buffers with and without Tween and
with and without EDTA were less successful. This procedure
was maintained throughout the study and with all newly
acquired anti-hTERT antibodies which became commercially
available (Ab 5 to Ab 11) (Table II).
The results of immunohistochemistry were compared with
control antibodies: a monoclonal mouse anti-human Ab 12
against Ki-67, a polyclonal rabbit antibody Ab 13 against
nucleolin and a monoclonal mouse Ab 14 against leukocyte
common antigen (Table II). Ki-67 was used to prove prolifer-
ation and for better recognition of carcinomas in the tiny
frozen sections; CD45 for better visualization of lymphocyte
mononuclear infiltration. After the monoclonal anti-hTERT
antibody (clone 44F12, code NCL-hTERT, Ab 3) was
described in the study by Wu et al (23) as an antibody against
nucleolin, we expanded our investigation and incorporated an
anti-nucleolin antibody (Ab 13) to clarify this issue.
Immunohistochemistry and immunoreactive score values
(IRS). All incubation steps taken in the immunohistochemical
staining process were performed in a humidified chamber. To
block non-specific reactions we incubated sections at room
temperature for 20 min with the ready-made X0909 blocking
buffer (DakoCytomation). Between each step the sections were
rinsed thoroughly three times in TBS buffer, pH 7.6 (Tris-
buffered saline, concentrated 10X, S3001 DakoCytomation;
with pH of dilution at 7.6). All antibodies were diluted in
S2022 (DakoCytomation, ready to use). We determined the
optimal dilution for each antibody in accordance with the
product data sheets. Antibodies were incubated for 60 min
at 37˚C in the drying oven and then for 30 min at room
temperature. In the case of some antibodies only a limited
number of tissues were stained.
The alkaline phosphatase anti-alkaline phosphatase
[APAAP (25)] used to detect the antigen antibody reaction
was carried out as follows: the two bridge antibodies were
incubated at room temperature at 1:40 (diluted in antibody
dilution plus 5% AB serum by Biotest AG, Dreieich, Cat.
805135/Germany). For sections with polyclonal primary anti-
bodies (for Ab 1, Ab 2, Ab 4 to Ab 9, Ab 13) monoclonal
mouse anti-rabbit bridge antibodies (DakoCytomation M0737)
were applied and for sections with monoclonal antibodies
(for Ab 3, Ab 10, Ab 11, Ab 12, Ab 14) polyclonal rabbit
anti-mouse bridge antibodies (DakoCytomation Z0259) were
used. Sections were then incubated for 40 min with the mono-
clonal APAAP complex (DakoCytomation D0651), diluted
1:100 in antibody dilution plus 5% inactivated fetal calf serum
(FKS, Biochrom AG, Berlin, S0115, Germany). Substrate
development lasted approximately 20 min (gauged by visual
judgment) with DakoCytomation K0624 substrate plus 2
additional drops of levamisol (K5000 by DakoCytomation)
per 3 ml of substrate. The sections were counterstained with
hemalaun (DakoCytomation S2020) for 5 min with subsequent
blueing for 5 min in tap water.
All score values given for anti-hTERT, Ki-67 and anti-
nucleolin refer exclusively to nuclear and/or nucleolar
stainings in the carcinomas or epithelia and the expression of
CD45 in complete tissues. Based on our previous immuno-
histochemical studies with other antibodies (26-28) we used the
immunohistochemical evaluation by Remmele et al (29,30).
The evaluation of the sections was performed three times at
different time points by an independent examiner and was
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Table II. Overview of primary antibodies used.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ab Antibodies Source, code Characterization Working 
code dilution
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ab 1 Polyclonal rabbit Oncogene Anti-hTERT (aa 348-358 of human hTERT). 1:10
anti-telomerase Ab (from Calbiochem, USA) IgG-Ab
code PC 563
Ab 2 Polyclonal rabbit Alpha Diagnostics Anti-hTERT against the 16-aa peptide EST21-P, 1:25
anti-EST-2 Ab International, USA sequence mapping in the middle of human EST-2 
(affinity pure) code EST21-A was selected for antibody production. The peptide was
coupled to KLH, antibody was generated in rabbit.
IgG1-Ab
Ab 3 Mouse monoclonal NovoCastra, UK Against procaryotic recombinant fusion protein 1:10
anti-telomerase code NCL-L-hTERT corresponding to a 148-aa truncate
(catalytic unit) liquid Ab (aa 173-320), a region near the N-terminal.
(clone 44F12) IgG2a-κ-Ab
Ab 4 Polyclonal rabbit Calbiochem, USA Immunogen used was a synthetic peptide 1:250
anti-telomerase Ab code 582005 corresponding to an internal region of the
catalytic subunit of human telomerase reverse
transcriptase (hTERT), recognizes the 
~125 kDa telomerase (TERT) protein.
IgG-Ab
Ab 5 Polyclonal rabbit Santa Cruz Against aa 900-1130 mapping at the 1:10
anti-TERT (H-231) Ab, Biotechnology Inc., USA C-terminus of TERT of human origin.
unconjugated code sc-7212 IgG-Ab
Ab 6 Polyclonal rabbit Calbiochem, USA Immunogen used was a synthetic peptide 1:250
anti-telomerase Ab code 582000 corresponding to amino acids from an internal
region of the catalytic subunit of human telomerase 
reverse transcriptase (hTERT), recognizes the
~125 kDa telomerase (TERT) protein.
IgG-Ab
Ab 7 Polyclonal rabbit Abcam, USA Immunogen a peptide from the mTERT 1:250
anti-telomerase Ab  code ab177 protein component from telomerase.
IgG-Ab
Ab 8 Polyclonal rabbit Abcam, USA Immunogen a synthetic peptide conjugated 1:25
anti-telomerase Ab code ab23699 to KLH derived from within residues
(affinity purified) 550-650 of human telomerase.
IgG-Ab
Ab 9 Polyclonal rabbit Rockland, USA The antibody was prepared from whole rabbit 1:50
anti-telomerase catalytic code 600-401-252 serum produced immunization with a synthetic
subunit (hTERT) peptide corresponding to a region near the
(affinity purified) carboxy terminal end of hTERT (aa 1104-1123).
IgG-Ab
Ab 10 Monoclonal mouse Novus Biologicals, USA Immunogen full-length recombinant hTERT 1:50
anti-telomerase code NB 100-297 from insect cells.
reverse transcriptase Ab IgM-Ab
(clone 2D8) 
1257-1279  24/3/2009  02:01 ÌÌ  ™ÂÏ›‰·1260
based on estimated values for staining intensity (SI: 0, no
staining; 1+, weak; 2+, moderate; 3+, strong and 4+, very
strong staining) and percentage of positive staining in tissue
sections (PP: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3,
51-75% and 4, 76-100% positive cells). The immunohisto-
chemical score value (IRS) was then calculated by multipli-
cation of SI and PP. The evaluation was performed with a
40-fold objective.
Immunoabsorption to test anti-hTERT antibody specificity.
Few commercial peptides were available for these tests: a
hTERT peptide EST21-P (Alpha Diagnostics), 16-aa peptide
of human EST2. This peptide was used as a homologous
immunogen for EST21-A, our Ab 2; a hTERT peptide ab24029
(Abcam, USA), a synthetic peptide derived from within
residues 550-650 of human telomerase, and was used as a
homologous immunogen for ab23699, our Ab 8; and a
nucleolin peptide ab25315 (Abcam), a synthetic peptide
derived from within residues 1-100 of human nucleolin, and
was used as a homologous immunogen for ab22758 nucleolin-
Ab, our Ab 13. Using Ki-67 antibodies by DakoCytomation
(Ab 12) we tested the suitability of albumin as a control
for absorption. We used a 30% albumin solution (Sigma
A-334424, USA) diluted 1:30 in isotonic buffered saline. The
immunoreactive score value of Ki-67 expression was the
same after absorption in the albumin solution as it was
before.
We conducted immunoabsorption following the protocols
of Alpha Diagnostics (31) and Abcam (32) with some
modification, and the details provided by Frost et al (33). The
antibody-peptide mixtures were incubated for 2 h at 37˚C and
overnight at 4˚C to facilitate absorption of antibodies binding
at higher and/or lower temperatures. For control purposes we
substituted peptide with the same quantity of albumin (Sigma
A-3424) and used the same volume of antibody dilution
(S2022, DakoCytomation). Following incubation we
centrifuged the mixtures for 15 min at 15000 rpm at 4˚C and
applied immunohistochemical techniques on the absorbed
portions (including the control portions with albumin) at the
usual dilution. Squamous cell carcinomas (30 tissues) and
control tissues (13 tissues) with squamous epithelium were
examined with the absorbed antibodies. We evaluated the
immunoabsorption on the basis of immunoreactive scores
of tissues before and after absorption. IRS unchanged after
absorption: immunoabsorption of antibody, negative; IRS
after slight absorption, 1+; IRS after absorption reduced by
half and more, 2+ to 3+. Only results of 2+ and 3+ were
considered adequate for our purpose. 
Determining telomerase activity in the same frozen tissue
samples. As described above (13,14), we used the test kits
TeloTAGGG Telomerase PCR ELISA (Roche Diagnostics,
Applied Science, Mannheim, Germany, catalogue no.
11854666910) and TeloTAGGG Telomerase PCR ELISAPlus
(Roche Diagnostics, catalogue no. 12013789001) for demon-
stration of telomerase activity. The frozen tissues were lysed
and the lysate adjusted with the addition of 0.5 and 5 μg protein
or, if necessary, amounts under 0.5 μg per PCR trial. We
conducted the examination following suppliers' instructions.
It was necessary to use the TeloTAGGG Telomerase PCR
ELISAPlus kit because its internal standards make it possible
to check for any false negative findings caused by inhibition
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Table II. Continued.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ab Antibodies Source, code Characterization Working 
code dilution
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Ab 11 Monoclonal mouse Novus Biologicals, Immunogen full-length recombinant hTERT from 1:100
anti-telomerase USA insect cells.
reverse transcriptase code NB 100-317 IgM-Ab
(clone 2C4)
Positive control antibodies
Ab 12 Monoclonal mouse Dako, Denmark Immunogen human recombinant peptide 1:100
anti-human Ki-67 antibody code M7240 corresponding to a 1002-bp Ki-67 cDNA fragment.
(clone MIB-1) IgG1-κ-Ab
Ab 13 Polyclonal rabbit Abcam, USA Immunogen synthetic peptide conjugated to KLH 1:400
antibody against nucleolin code ab22758 derived within residues 1-100 from human nucleolin.
IgG
Ab 14 Monoclonal mouse Dako, Denmark Reacts with B cell, T cell subsets, monocytes, 1:100




aa, amino acid; Ab, antibody; KLH, keyhole limpet hemocyanin.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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of the PCR. With a subsequent ELISA it was then possible to
detect telomerase activity (TA) in mOD and classify TA into
five groups: 0, negative, TA 0-150 mOD; 1+, TA 150-450
mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA
above 1050 mOD. The telomerase levels had to be correlated
with immunohistochemical hTERT scores.
Statistical evaluation. For statistical evaluation (34), SPSS 15.0
for Windows, version 15.0.1 was available (35). Apart from the
descriptive statistics, we compared median values using the
Mann-Whitney U test or, if distribution was normal, we
compared mean values using the t-test. Given the relatively
small number of patients, we reduced all values into two
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Table III. Telomerase activity in mOD and expression of hTERT and of control antibodies Ab 12 to Ab 14 (Table II) by IRS
in tumor center tissues of oral and extraoral squamous cell carcinomas (patients data see Table I).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. TA-TCa IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS
Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ab 8 Ab 9 Ab 10 Ab 11 Ki-67 Ab 13 CD45
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 0 0 12 6 4 12 7 6 12 8 12 10 12
2 0 2 9 4 1 3 - 11 10 - 12 12 4
3 4+ 4 0 1 1 11 2 7 11 6 10 11 6
4 4+ 5 12 16 5 12 9 11 10 8 10 10 12
5 4+ 8 12 12 4 16 12 12 6 8 12 12 6
6 4+ 0 8 12 6 10 6 11 9 12 12 12 1
7 1+ 1 9 6 6 6 - - 0 - 12 - 12
8 4+ 0 0 6 2 4 1 6 11 11 8 8 6
9 1+ 8 12 11 3 11 3 9 12 0 14 12 12
10 0 0 12 7 4 2 - - - - 12 - 8
11 4+ 1 12 12 9 1 - - - - 10 - 8
12 2+ 1 8 8 8 3 - 2 - - 12 5 16
13 4+ 5 9 16 3 11 10 12 9 9 16 14 4
14 4+ 1 12 12 4 9 - - - - 12 - 4
15 4+ 2 11 6 0 5 1 4 - 7 4 12 5
16 2+ 8 12 6 - 11 8 3 11 0 12 12 6
17 4+ 0 12 5 3 8 - - - - 7 - 7
18 4+ 1 1 7 2 7 - - - - 6 - 3
19 4+ 2 1 7 4 2 - - - - 12 - 8
20 0 0 8 4 1 6 - - - - 8 - 12
21 4+ 3 5 11 6 6 - - - - 16 - 16
22 3+ 1 12 4 4 9 - - - - 12 - 12
23 1+ 0 3 5 5 4 - - - - 12 - 6
24 2+ 0 8 1 1 6 8 10 8 11 10 12 4
25 4+ 0 8 7 0 6 9 - - - 8 12 6
26 2+ 9 12 3 1 10 12 11 14 7 16 12 12
27 3+ 5 12 12 9 9 - - - - 12 - 8
28 4+ 6 8 16 6 11 11 6 6 1 10 12 6
29 3+ 2 12 5 0 5 - - - - 12 - 6
30 4+ 8 8 8 3 14 14 11 9 9 12 8 16
31 2+ 1 6 4 2 7 2 - 8 2 12 - 12
32 2+ 1 8 11 3 4 - - - - 12 - 16
33 4+ 2 5 12 6 7 - - - - 8 - 8
34 4+ 0 14 6 1 8 10 9 11 9 12 12 12
35 3+ 0 8 11 4 12 - 8 - 5 8 10 1
36 4+ 5 3 12 4 2 - - - - 8 - 12
37 1+ 12 8 12 6 11 8 - 14 5 12 11 16
38 4+ 0 12 9 5 7 2 12 9 9 12 12 2
39 3+ 4 12 12 2 11 3 6 8 9 10 12 12
40 2+ 2 7 8 2 8 4 5 7 4 16 8 12
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aTA-TC, telomerase activity in total tumor center; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-
1050 mOD; 4+, TA above 1050 mOD; TC, tumor center; IRS, immunoreactive score; Ab, antibody: Table II; -, not examined.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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groups for the statistical comparison of incidence (immuno-
reactive score values and telomerase activity) in the ¯2 test or
Fisher exact tests. We divided all values into two groups: for
group 0, values < median value and for group 1, values ≥
median value. We chose the median value as the cut-off value
because the score values were not normally distributed.
For testing the prognostic statement made by these values
in the Kaplan-Meier curves we used the patient outcome
documentation in our hospital. We recorded the number of
months between tissue excision and relapse. Several patients,
particularly patients with extraoral HNSCC, withdrew from
the follow-up. We applied to the Kaplan-Meier curves with the
hTERT-group 0 (values < median value) and hTERT-group 1
(values ≥ median value).
Test results with p≤0.05 were rated as statistically
significant.
Results
Since proof of hTERT expression was very weak with both the
first antibody (polyclonal anti-telomerase Ab, Oncogene code
PC 563) and the fifth antibody (polyclonal anti-TERT Ab
H-231, Santa Cruz code sc-7212) (Table II), we used these two
antibodies only for a few sections and did not detail the results.
The score values for all tissues without carcinoma cells
and without squamous epithelium were very low (tendency
towards 0) and for this reason were neither listed nor presented
in a graph.
Results for tissues from tumor patients: hTERT expression
in the tumor center. Tables III and IV summarize the
immunoreactive score values for hTERT expression in
comparison to telomerase activity as determined by PCR in
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Table IV. Telomerase activity in mOD in tumor center tissues, expression of hTERT and Ki-67 by IRS of squamous epithelia
(SE) in the oral and extraoral squamous cell carcinoma tissue samples (see Table I).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. TA-TCa IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS
Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ab 8 Ab 9 Ab 10 Ab 11 Ki-67
SE SE SE SE SE SE SE SE SE SE
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
1 0 4 8 - 0 6 - 5 9 5 8
4 4+ 5 6 - 5 8 - 6 8 5 8
5 4+ - - 0 - - - - - - -
6 4+ 2 8 8 3 8 - 8 7 11 2
7 1+ 1 6 8 4 4 - - 1 - 12
9 1+ 6 12 - 3 7 4 6 9 1 8
10 0 0 7 12 2 5 - - - - 12
12 2+ 0 12 - 1 12 - - - - 12
14 4+ 1 7 - 8 8 - - - - 8
17 4+ 0 9 - 6 2 - - - - 3
19 4+ 5 12 - 5 2 - - - - 12
20 0 - - 3 - - - - - - -
21 4+ 6 11 11 6 6 - - - - 8
22 3+ 1 6 - 2 6 - - - - 6
23 1+ 0 8 - 1 2 - - - - 16
24 2+ - 8 10 - - - 9 9 9 -
25 4+ 0 1 - 7 8 - - - - 8
26 2+ 6 2 0 1 9 10 9 10 5 12
27 3+ - - 14 - - - - - - -
28 4+ - - 6 - - - 5 7 1 -
29 3+ - 12 9 - 8 - - - - 12
30 4+ - 2 - - - - 7 8 5 12
31 2+ - - 7 - - - - 8 3 -
32 2+ 0 2 3 1 4 - - - - 12
33 4+ 6 3 - 4 7 - - - - 10
35 3+ 0 6 - 4 5 - 6 - 4 12
36 4+ 1 2 6 1 1 - - - - 2
39 3+ 0 12 2 0 6 3 4 6 4 8
40 2+ 0 3 5 1 1 5 2 3 3 12
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aTA-TC, telomerase activity in total tumor center tissue; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA
750-1050 mOD; 4+, TA above 1050 mOD; IRS, immunoreactive score; Ab, antibody: Table II; -, no squamous epithelium in section or not
examined.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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the same tumor center tissue samples. Patient data are given
in Table I.
Telomerase activity and hTERT expression yielded with
antibodies Ab 3, Ab 6, Ab 8 and Ab 11 as well as with anti-
nucleolin antibody (Ab 13) were higher in oral carcinoma
(n=33, patients nos. 1-33) than in extraoral carcinoma (n=7,
patients nos. 34-40). With the other hTERT antibodies (Ab 2,
Ab 4, Ab 7, Ab 9, Ab 10) the values were either the same or
higher in extraoral tissue. The U test (or t-test) rendered no
significant difference in IRS between oral and extraoral
carcinoma tissue: either in anti-hTERT scores, scores for telo-
merase activity, scores for Ki-67, anti-nucleolin or CD45. The
p-values ranged between 0.136 and 1.000. Localization of the
tissue was therefore disregarded in the subsequent results.
The score values of individual antibodies were very
heterogeneous, both in squamous cell carcinoma tissue and
the squamous epithelium of the same tissue sample, and
antibodies for the most part were not distributed normally
(Tables III and IV). For this reason the median values for
hTERT-expression in Fig. 1 were depicted as graphics.
IRS median values in Fig. 1 reveal that the polyclonal
antibodies anti-EST2 (Ab 2) and the anti-telomerase Ab by
Calbiochem (code 582000, Ab 6) are least suited for hTERT
demonstration in frozen sections and show significantly less
hTERT expression in the tissues than do other antibodies.
hTERT expression with both these antibodies was however
higher than that observed with the two other antibodies not
included in Tables III and IV, namely the anti-telomerase Ab
code PC 563 by Oncogene (Ab 1) and the Ab 5 (anti-TERT
H 231, code sc-7212 by Santa Cruz).
The statistical comparison of immunoreactive score values
for the individual antibodies as determined in the Mann-
Whitney U test (or t-test) shows, as does Fig. 1, that the
immunohistochemical scores in the squamous carcinomas with
the anti-hTERT-antibodies Ab 3, Ab 4, Ab 6 and Ab 7 to
Ab 11 are statistically significantly higher than with antibody 2
(code EST21-A) (Tables III and IV). The score values achieved
with Ab 6 (Calbiochem code 582000) are statistically signifi-
cantly lower than those achieved with Ab 3, Ab 4 and Ab 7
to Ab 11. The score values with Ab 10 (code NB 100-297)
are for all tests higher than those yielded by all the other
antibodies, and significantly higher than with Ab 2 (p<0.01),
Ab 6 (p<0.01), Ab 8 (p=0.035) and Ab 11 (p=0.029). Score
values with Ab 3 (NovoCastra clone 44F12) are only lower
than those with the antibodies Ab 9 and Ab 10. In no test was
the difference significant. 
The score values for hTERT expression with all anti-
hTERT antibodies were higher in carcinoma than in normal
or partly dysplastic squamous epithelium present in the same
tissue sample (Tables III and IV, Fig. 1). In the U test (or
t-test) hTERT expression in carcinoma was, however, not
always significantly higher than in squamous cell tissue of
the same piece of tissue: Ab 2, p=0.412; Ab 3, p=0.056; Ab 4,
p=0.081; Ab 6, 0.463; Ab 7, p=0.032; Ab 8, p=0.528; Ab 9,
p=0.024; Ab 10, p=0.012 and Ab 11, p=0.043.
In the ¯2 test we explored whether there is a statistical
correlation between hTERT expression in the individual anti-
bodies and telomerase activity in squamous cell carcinoma, and
formed two groups for this purpose (see statistical evaluation):
p-values between 0.086 and 0.876. It appeared to be the
lowest (p=0.086) with the monoclonal antibody (clone 2C4)
NB 100-317 (Ab 11). This might be because this particular
antibody lot had to be filtered and centrifuged to remove
foreign particles.
In the same manner we examined expression of Ki-67,
nucleolin and CD45 (Table III). No statistical difference was
found in the tumor center between the scores with Ki-67
(Ab 12) and with anti-nucleolin (Ab 13): U test, p=0.828.
However, both these scores differed significantly from the
proof of lymphocytic infiltration as indicated by the scores
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Figure 1. Median values of immunohistochemical score values (IRS) for hTERT expression in the squamous cell carcinomas and squamous epithelium in the
same tissue samples. Ab see Table II. 
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with CD45 (Ab 14) of all tissue types of the tumor centers:
U test, p=0.008 and 0.041. In the ¯2 test (or Fisher exact test)
the hTERT expression was compared with the expression of
the control antibodies. In the comparison of both Ki-67 and
of nucleolin scores with hTERT score values a correlation
appears ranging in significance from slight to high. A
significant divergence (p=0.036) appears between nucleolin
expression and hTERT scores with the monoclonal anti-hTERT
antibody NCL-hTERT (Ab 3). This contradicts observations
made by Wu et al (23). The other p-values are located
between 1.000 and 0.191. Between the nucleolin and CD45
expression and telomerase activity there is also a statistical
correlation, but not between Ki-67 and telomerase activity
(p=0.05).
Expression of hTERT in tumor-free tumor margin and tumor
distant tissue from the patients with squamous cell carcinoma.
Table V summarizes the immunoreactive scores for hTERT
expression in the squamous epithelium of the carcinoma-free
tumor margin and carcinoma-free tumor distant tissue. The
scores for Ki-67 in squamous epithelium and evidence of
lymphocytic infiltration by CD45 in the tissue samples are
also shown. Fig. 2 presents the median values for hTERT
expression on squamous epithelium in these tissues.
Evidence for hTERT expression in squamous epithelium is
also more moderate as detected by both polyclonal anti-hTERT
antibodies, the anti-EST2 (Ab 2) and the anti-telomerase Ab
from Calbiochem (code 582000, Ab 6): Fig. 2 (see Fig. 1). A
comparison of hTERT score values, as determined with the
U test (or t-test) renders no significant difference between
hTERT score values for squamous epithelium in the tumor
center, in the tumor margin or in tumor distant tissue, i.e., the
values for hTERT expression in these regions are correlated:
the hTERT expression in the squamous epithelium adjacent
to the carcinoma is statistically no higher than that in the
more distant tissue: p-values between 0.114 and 0.972.
Using the U test (or t-test) we also compared score values
for expression of Ki-67 in squamous epithelium and proof of
CD45-positive lymphocytic cells in the same tissue areas.
Evidence of proliferating epithelial cells (Ki-67 scores) did not
differ significantly among the three regions, but lymphocytic-
monocytic infiltration was the lowest in the tumor distant
region: p=0.974 (Ki-67) and p=0.068 (CD45). There is a
correlation between the level of hTERT scores and the intensity
of CD45 staining of the lymphocytic infiltration in tumor
margin and tumor distant tissue. The correlation was significant
only between CD45 and the lowest hTERT scores observed
with the antibodies Ab 2 and Ab 6 (p<0.001). 
With the ¯2 test we addressed the question of whether
there is a correlation between hTERT expression, Ki-67 score
values in epithelium, evidence of CD45 in the resection margin
and tumor distant tissue, and telomerase activity in the same
tissue. No statistical relation was found between telomerase
activity in tumor margin tissue and hTERT expression when
the polyclonal anti-hTERT antibody EST-2 (Ab 2) was used
(tumor margin p=0.038, tumor distant values p=0.103), and
only a slight correlation was found with the monoclonal anti-
body code NCL-hTERT (Ab 3): p=0.055 (tumor margin) and
p=0.103 (tumor distant tissues). We did find a statistical
relationship between hTERT expression with the other hTERT-
antibodies and telomerase activity in the same tissue (p-values
of tumor margin between 0.884 and 0.421 and tumor distant
tissues between 1.000 and 0.580). The Ki-67 score values
(tumor margin p=0.052 and tumor distant tissues p=0.580) and
the CD45 score values for lymphocytic infiltration (tumor
margin p=0.751 and tumor distant tissues p=1.000) were also
connected to telomerase activity in the same tissue. This
correlation was the weakest in squamous epithelium of the
tumor margin.
Expression of hTERT in control tissue. Resulting immuno-
reactive hTERT score values for squamous epithelium are
INTERNATIONAL JOURNAL OF ONCOLOGY  34:  1257-1279,  2009 1265
Figure 2. Median values of immunohistochemical score values (IRS) for hTERT expression in squamous epithelium in tumor margins and in tumor distant tissues
from the HNSCC. Ab see Table II.
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Table V. Telomerase activity in mOD, expression of hTERT and of Ki-67 in squamous epithelium from the tumor-free
margins (TM) and tumor-free tumor distant tissues (TD) of squamous cell carcinomas as well as of lymphatic infiltration
(expression of CD45 in complete sections), see Table I.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
No. TAa- IRS IRS IRS IRS IRS IRS IRS TAa- IRS IRS IRS IRS IRS IRS IRS
TM Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ki-67 CD45 TD Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ki-67 CD45
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
SE TM SE TD
2 - - - - - - - - 0 1 5 - - - 4 1
5 1+ 0 4 0 0 2 1 3 0 2 8 0 0 2 8 8
6 0 1 8 8 3 4 8 4 0 - - 8 3 4 - 1
7 2+ 7 6 8 1 6 3 8 0 - - 8 1 6 - 0
9 - - - - - - - - 1+ 0 12 - - - 12 5
10 1+ 1 12 12 0 14 6 11 0 - - 12 0 14 - 2
12 - - - - - - - - 1+ 1 6 - - - 8 1
15 - - - - - - - - 4+ 0 3 - - - 12 8
20 0 1 10 3 3 12 8 4 - - - - - - - -
21 4+ 1 8 11 4 6 12 16 0 - - 11 4 6 - 4
24 2+ 11 3 10 5 10 12 12 0 6 6 10 5 10 12 4
26 2+ 0 0 0 0 12 12 2 0 2 8 0 0 12 4 12
27 0 0 9 14 0 9 12 12 - - - - - - - -
28 0 6 12 6 4 3 8 7 - - - - - - - -
29 0 9 12 9 2 1 1 6 1+ 0 1 9 2 1 8 12
31 3+ 2 5 7 3 6 12 8 0 2 12 7 3 6 8 4
32 0 5 12 3 7 5 12 16 - - - - - - - -
36 1+ 0 5 6 3 5 4 12 - - - - - - - -
38 0 - - - - - - 2 0 2 3 - - - 12 3
39 1+ 0 6 2 2 3 8 8 0 3 12 2 2 3 2 8
40 2+ 3 8 5 2 0 8 1 - - - - - - - -
41 0 - 9 - - - 0 0 - - - - - - - -
42 1+ 2 8 5 2 5 4 12 - - - - - - - -
43 0 2 1 1 1 1 12 1 - - - - - - - -
44 2+ 5 5 11 5 6 8 8 - - - - - - - -
45 1+ 1 8 8 2 16 16 12 - - - - - - - -
46 0 - - - - 11 4 8 - - - - - - - -
47 1+ 8 11 8 8 10 12 12 - - - - - - - -
48 3+ 6 7 1 1 5 8 12 0 1 9 1 1 5 12 12
49 2+ - - 6 - - 12 0 - - - - - - - -
50 3+ 11 4 4 4 5 12 8 - - - - - - - -
51 1+ 4 10 3 - 3 8 12 - - - - - - - -
52 0 1 2 0 - - 8 3 - - - - - - - -
53 0 1 14 5 4 14 12 10 - - - - - - - -
54 2+ 5 7 10 10 10 8 4 - - - - - - - -
55 2+ 0 1 0 0 0 8 16 0 - 10 0 0 0 12 4
56 1+ 12 14 14 5 11 16 14 - - - - - - - -
57 3+ 4 6 6 2 6 8 8 1+ 0 0 6 2 6 4 0
58 2+ 2 0 8 6 - 2 4 - - - - - - - -
59 1+ 6 12 12 6 6 8 4 - - - - - - - -
60 1+ 0 8 8 4 8 8 12 - - - - - - - -
61 4+ 2 14 2 0 14 12 4 - - - - - - - -
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
aTA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD; 4+, TA
above 1050 mOD; TM, carcinoma-free tumor margin tissue; TD, tumor distant tissue; SE, squamous epithelia; IRS, immunoreactive scores;
Ab, antibody: Table II; -, no squamous epithelium in section or was not examined.
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listed in Table VI and median values are illustrated in
Fig. 3.
Fig. 3 illustrates the low sensitivity of antibodies Ab 2 and
Ab 6, disqualifying them for detection of hTERT expression
in control tissues. As already distinguishable in Fig. 3 (see
Figs. 1 and 2) the score values for the antibodies Ab 2 and
Ab 6 are consistently lower than those for the other antibodies.
The immunoreactive scores of control tissue samples
also were very heterogeneously distributed in the squamous
epithelium itself and varied with the individual antibody.
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Table VI. Telomerase activity in mOD and expression of hTERT and of Ki-67 in oral and extraoral squamous epithelia of
control tissue (IRS).
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Control TAa IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS IRS
no. Ab 2 Ab 3 Ab 4 Ab 6 Ab 7 Ab 8 Ab 9 Ab 10 Ab 11 Ab 12 Ab 13 Ab 14
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
23 oral tissues
Co 1 2+ 0 4 2 3 3 - - - - 1 - 1
Co 2 2+ 8 6 12 12 12 12 6 - 0 12 - 12
Co 3 0 6 14 14 14 12 10 - - - 12 - 12
Co 4 0 8 12 12 2 12 8 10 8 8 10 12 8
Co 5 4+ 1 16 3 3 9 - - 10 - 3 - 7
Co 6 2+ - 8 - - - - - - - 8 - 4
Co 7 0 0 8 5 1 3 - - - - 12 - 12
Co 8 0 5 8 5 - 12 11 5 10 6 12 12 8
Co 9 0 - 8 8 - 14 6 8 9 8 4 8 2
Co 10 2+ 2 10 12 4 12 - - - - 12 - 4
Co 11 2+ 0 10 8 8 12 - - - - 8 - 4
Co 12 0 10 10 12 0 11 2 4 - 4 12 12 8
Co 13 1+ 0 10 1 1 2 - - - - 8 - 12
Co 14 3+ 2 4 8 3 8 - - - - 4 - 4
Co 15 2+ 4 12 14 3 12 - 5 - - 12 - 8
Co 16 0 0 - 10 0 10 - - - - 12 - 12
Co 17 0 0 2 16 6 4 3 12 16 - 12 - 8
Co 18 0 2 2 7 2 4 12 12 0 8 12 - 2
Co 19 2+ 9 5 12 9 10 11 12 - 9 12 - 8
Co 20 0 2 12 12 6 8 - - 6 0 12 - 8
Co 21 0 5 10 7 3 7 - - - - 8 - 2
Co 22 0 - - - - - 8 8 - - 8 12 -
Co 23 2+ 1 1 12 5 5 - - - - 8 - 12
14 extraoral tissues
Co 24 0 2 9 2 2 1 0 4 5 - 8 8 6
Co 25 0 1 1 12 5 0 - - - - 1 - 3
Co 26 0 4 8 12 9 6 - - - - 8 - 8
Co 27 0 - 0 - - 0 - - - - 8 - 0
Co 28 0 0 6 1 1 8 5 10 9 12 8 10 9
Co 29 0 0 6 6 2 0 - - - - 8 - 2
Co 30 1+ 4 0 12 2 0 - - - - 4 - 8
Co 31 0 2 4 8 0 5 - - - - 4 12 0
Co 32 0 0 8 6 0 9 11 12 12 9 4 9 8
Co 33 0 5 12 14 5 12 12 8 12 10 8 14 12
Co 34 0 0 2 10 2 8 0 16 14 11 8 - 5
Co 35 0 0 12 8 0 7 4 1 8 0 2 8 0
Co 36 0 1 6 7 15 5 - - 2 - 8 - 1
Co 37 0 0 8 1 0 0 - - - 11 - - 8
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Co, control no.; aTA, telomerase activity; 0, negative, TA 0-150 mOD; 1+, TA 150-450 mOD; 2+, TA 450-750 mOD; 3+, TA 750-1050 mOD;
4+, TA above 1050 mOD; Ab, antibody: Table II; IRS, immunoreactive scores; -, not examined or no squamous epithelium in section.
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When the immunoreactive score values of oral and extraoral
control tissues were compared in the U test (or the t-test), it
was frequently the squamous epithelium of oral tissue which
in most tests showed the highest expression. This difference,
however, was rarely significant (oral scores were higher
with Ab 6, p=0.052; and significantly higher with Ab 7,
p=0.010; extraoral scores were significantly higher with Ab 11,
p=0.043). With all other antibodies, the difference in expression
between oral and extraoral squamous cell carcinoma was
insignificant (p-values between 0.103 and 0.886).
Telomerase activity and the expression of Ki-67 (Ab 12),
nucleolin (Ab 13) and CD45 (Ab 14) were higher in oral
control tissues than in extraoral tissues (Table V). This
difference was significant for telomerase activity (p=0.023),
Ki-67 (p=0.006) and CD45 expression (p=0.032) but was not
significant for nucleolin expression (p=0.434).
The ¯2 test between telomerase activity in the control tissues
and the hTERT-score values as well as between telomerase
activity in the control tissues and the scores for control anti-
bodies showed a connection (all p-values were >0.05).
Testing the specificity of anti-hTERT antibodies by immuno-
absorption. While this study was in progress, Wu et al (23)
reported that the monoclonal anti-hTERT antibody NCL-
hTERT clone 44F12 (Ab 3) primarily identifies nucleolin
rather than hTERT. The Wu group supported this with mass-
spectrometry evidence as well as gel analysis and immuno-
fluorescence. Since immunohistochemical in situ presentation
requires an antigen-antibody reaction, we expanded our study
to include immunoabsorption of some of our antibodies with
two commercially available peptides and one nucleolin peptide.
We used the hTERT peptide EST21-P, homologous to the
anti-hTERT antibody (Ab 2), the hTERT peptide ab24029,
homologous to anti-hTERT antibody Ab 8 and the nucleolin
peptide ab25315, homologous to the anti-nucleolin antibody
(Ab 13). After immunoabsorption with hTERT peptide EST
21-P and nucleolin peptide, the amount of resulting precipitate
was negligible. This was the case both with the homologous
antibodies and with the other anti-hTERT antibodies. There
was, however, significant precipitate, i.e., precipitating antigen-
antibody complexes, after immunoabsorption with the hTERT
peptide and the homologous antibody Ab 8 and also with the
anti-hTERT antibodies Ab 4, Ab 7, Ab 9 and Ab 10. Somewhat
less precipitate resulted with Ab 11. The immunoabsorption
of Ab 3 exhibited significant precipitate. In contrast, no
precipitate was deposited after immunoabsorption of the anti-
nucleolin antibody, either with the two hTERT peptides or
with the homologous nucleolin peptide.
After immunoabsorption and centrifugation of the
precipitate, we determined the immunoreactive score values
with the absorbed antibodies and compared them before and
after absorption. We then determined the percentage of tissues
with score values which were markedly lower after absorption
than before (2+ or 3+ inhibition of score values by absorption).
After incubation with peptide, some of the antibodies showed
no or little change in score value (rated as negative immuno-
absorption). This might be because the antibody corresponded
only partially to the peptide, or, as is more likely, because too
little peptide was applied. This was clearly evident with the
polyclonal antibodies EST21-A (Ab 2) and ab23699 (Ab 8),
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Figure 3. Median values of immunohistochemical score values (IRS) for hTERT expression in control tissues with squamous epithelium. Ab see Table II.
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which even with the homologous peptide used in their
production showed only 60% and 59% absorption respectively.
Adding inert albumin to the antibodies instead of peptide did
not reduce their score values. Since the reduced score values
resulting in carcinoma tissue and in the squamous cell tissues
from the controls were comparable, we summarized absorption
results for the anti-hTERT antibodies together in Fig. 4.
Fig. 4 shows the percentage of score values after immuno-
absorption. The figure shows that only the anti-hTERT Ab 11
(code NB 100-317) was completely absorbed by the hTERT
peptide EST-21-P and only the anti-nucleolin antibody (Ab 13)
was completely absorbed by the homologous nucleolin peptide
ab25315. The score values for antibodies Ab 4 and Ab 9 to
Ab 11 remained unchanged after absorption with the nucleolin
peptide ab25315 antibody.
The nucleolin peptide ab25315 absorbed three of the seven
anti-hTERT antibodies examined. The monoclonal antibody
NCL-hTERT (clone 44F12, Ab 3), characterized by Wu et al
as an anti-nucleolin (23), absorbed 21% of the number of
sections examined with the nucleolin peptide (79% was not
absorbed, Fig. 4). Similar immunoabsorption (17%) was
observed for the polyclonal ab177 (Ab 7, 83% not absorbed)
and a stronger absorption (57%) by the polyclonal ab23699
(Ab 8, 43% not absorbed). Conversely, the anti-nucleolin anti-
body (Ab 13) is only minimally absorbed (8% of the tissue
examined, 92% not absorbed) by the hTERT peptide ab24029,
the immunogen for the polyclonal ab23699, Ab 8.
Localizing hTERT with selected anti-hTERT antibodies. The
distribution of hTERT-positive cells was usually very hetero-
geneous in the individual squamous cell carcinomas irrespec-
tive of the antibody used. Where squamous epithelium in
tissues from tumor patients or in control tissue was still normal,
the hTERT-positive cells were limited to one or two basal
layers. However, in hyperplastic or more or less severely
dysplastic squamous epithelium, suprabasal hTERT was also
evident, or was spread over the entire squamous epithelium.
Fig. 5 compares the patterns of expression as indicated by
the individual anti-hTERT antibodies after pretreatment of the
frozen sections in the steamer and visualization in APAAP (25).
Fig. 5 shows some of the immunohistochemical illustrations
collected in carcinoma tissues. Application of the polyclonal
Ab 2 (not illustrated), polyclonal Ab 4 (Fig. 5b), polyclonal
Ab 8 (Fig. 5d), polyclonal Ab 9 (Fig. 5e), monoclonal Ab 10
(Fig. 5f) and monoclonal Ab 11 (not illustrated) induced the
typical immunohistochemical pictures of carcinoma and (not
illustrated) epithelia staining of the entire nucleus including
cytoplasmic staining. With the Ab 4 and Ab 11 we were also
able to distinguish non-specific staining in the uppermost
keratinous squamous epithelia or background (especially with
Ab 4). Positive staining was also observed with Ab 4, Ab 8
Ab 9 and Ab 11 in endothelia, lymphocytes/histiocytes or
blood cells (not illustrated).
The immunohistological pictures presented by the poly-
clonal Ab 6 are similar to Ab 4 but clearly weaker, with the
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Figure 4. Immunoabsorption of antibodies: 100%, there was no absorption in any tissues; 0%, complete absorption in all tissues.
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background also clearly weaker than with Ab 4. The pictures
with the polyclonal Ab 7 (Fig. 5c) and with the monoclonal
Ab 10 (Fig. 5f) demonstrated nuclear staining of the entire
nucleus, with but little background staining or non-specific
staining in the uppermost keratinous squamous epithelia (not
illustrated). Ab 10 also stained endothelia, lymphocytes/
histiocytes in connective tissues.
The immunohistochemical pictures of monoclonal Ab 3
(Fig. 5a) were nuclear, with characteristic marking of nucleoli
only. Background staining was not observed.
Prognostic significance of immunohistochemical proof of
hTERT protein. In order to determine the prognostic
significance of hTERT expression we applied Kaplan-Meier
curves as described under Patients and methods for each
antibody in the carcinoma tissue, in the squamous epithelium
in tumor center and tumor margin tissue. The Kaplan-Meier
analyses rendered no significant correlation between increased
hTERT expression and poor prognosis. The period without
recurrence was not significantly shortened in patients with
higher hTERT expression (scores ≥ the median value). The
Kaplan-Meier curves in Fig. 6 show that the increased hTERT
expression obtained with the polyclonal Ab 7 (code ab177)
correlated with a poor prognosis. The period without recurrence
was shortened in patients with hTERT expression ≥ IRS-
median.
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Figure 5. Typical immunohistochemical presentation of hTERT expression (Tables II and III) in oral squamous cell carcinoma (frozen sections) with some anti-
hTERT antibodies: a, Ab 3 (NCL-hTERT); b, Ab 4 (code 592005); c, Ab 7 (code ab177); d, Ab 8 (code ab23699); e, Ab 9 (code 600-401-252) and f, Ab 10 (code
NB 100-297); bar, 20 μm.
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Discussion
The telomeric repeat amplification protocol (TRAP) developed
in 1994 by Kim et al (16) made possible the reproducible
demonstration of telomerase in larger studies of various
tumors. Since then researchers have been working on hTERT
evidence with RT-PCR (12,18,19,36-40) or on proof of telo-
merase-positive cells by in situ hybridization (12,36-40). This
period has also seen the advent of laboratory manufacturing
(33,41-46) or commercial (17-22) production of anti-hTERT
antibodies for use in immunohistochemistry.
The purpose of the present study was the in situ demon-
stration of telomerase activation in frozen sections from head
and neck tumors and comparison with control tissue from
tumor-free patients. In previous studies with these same tissues
we had proved telomerase activity in PCR-ELISA (13-15) and
determined the corresponding semiquantitative extinction
values. Non-carcinomatous tumor margin tissue showed
telomerase activation. We wanted to identify the cells
responsible for this activity in non-carcinomatous tumor
margin and tumor distant tissue and chose as our method the
immunohistochemical proof of hTERT, the catalytic subunit
of telomerase, in the same frozen tissues in which we had
already demonstrated telomerase activity. We were obliged
to use commercial antibodies. Some anti-hTERT antibodies
gradually became available on the market through the
course of our study. At that time, non-commercial (33,41-46)
or commercial (17-22) antibodies had only been used for
hTERT-proof in paraffin slices or in paraffin-embedded
cells.
Immunoreactive hTERT score values in tissue from patients
with HNSCC. The relatively heterogeneous tissue examined
from patients with an HNSCC (patient data in Table I) was
derived from tumors with various staging and grading. The
squamous epithelium in these tissue samples also evidenced
different histopathological pictures. The small patient number
did not allow subdivision of hTERT results into individual
groups. We correlated hTERT expression both between the
different tissue regions (tumor center, carcinoma-free adjacent
tumor margins and tumor distant tissues) and with telomerase
activity (Tables III-V). It is clear from hTERT expression in
carcinoma (Table III, Figs. 1 and 5), in squamous epithelial
tissue of the tumor center tissue (Table IV and Fig. 1),
squamous epithelial tissue of the tumor margin (Table V and
Fig. 2) and squamous epithelial cells of tumor distant tissue
(Table V and Fig. 2) that the antibodies Ab 4 (code 582005)
and Ab 7 (code ab177) can be used for proof of hTERT.
Notwithstanding the re-evaluation of anti-hTERT antibody-
specificity by Wu et al (23), Ab 3 (NCL-L-hTERT) can be
used also for hTERT-detection. The antibodies Ab 8 to Ab 11,
which we used only for tumor center tissue (carcinoma and
squamous epithelium), also showed unambiguous immuno-
histochemical hTERT scores (Fig. 1 and Table III). hTERT
scores were higher in the carcinoma than in the squamous
epithelial tissue in the same tissue pieces. hTERT expression
in the squamous epithelium of tumor margins and tumor distant
tissue, however, was higher than or equal to the squamous
epithelium in carcinoma tissues.
The patterns of hTERT expression in these frozen sections
did not vary essentially from the picture presented on the
paraffin sections from HNSCC already examined (47-51).
With an antibody not described in more detail, Nguyen et al
(47) demonstrated hTERT in all carcinomas examined and,
albeit significantly less, in dysplastic squamous epithelia. The
authors (47) suppose a correlation between hTERT expression
and tumor stage. Kumar et al (48) examined hTERT expression
at different stages of oral carcinogenesis using the antibody
NCL-hTERT (our Ab 3, Table II) and were able to differentiate
between hTERT expression in normal oral mucosa and that
in different histological stages of oral carcinogenesis. The
authors evaluated only sections in which they had demonstrated
more than 50% hTERT-positive nuclei.
Luzar et al (49) also used hTERT proof with the antibody
NCL-hTERT for their study on the carcinogenesis of the larynx
carcinoma. They proved an increase in hTERT expression from
normal epithelium (average index 0.17) up to that in the
carcinoma (average index 0.96). In their extensive study,
Chen et al (50) also used the NCL-hTERT antibody and
differentiated their results by quantifying the proportions of
cytoplasmic and nuclear staining. They examined 21 tissues
from oral mucosa, 116 tissues of varying grades of dysplasia
and 62 oral SCC tissues and determined hTERT scores
comparable with those detected in our study. Immunohisto-
chemical scores are known to be higher on paraffin sections
than on frozen sections, a phenomenon which we have
already confirmed in earlier investigations (27,28). For their
scores, Chen et al (50) multiplied the percentage of positive
cells by staining intensity, while, in accordance with Remmele
et al (29,30), we reduced the percentage of positive cells
between 0 and 100% to 0 to a maximum of 4 and then
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Figure 6. Outcome in 40 patients with a squamous cell carcinoma and hTERT
score values with the polyclonal Ab 7 (code ab177) in the tumor center tissues:
Kaplan-Meier curve, Log-rank test p=0.138. The mean time period which
elapsed until relapse in 20 patients with hTERT score value ≥ median value in
carcinoma was 29±11 months, in 20 patients with score value < median value
was 62±13 months.
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multiplied this by staining intensity. Our scores lay under the
values of Chen et al (50) for the paraffin sections. Using the
antibody NCL-hTERT Chen et al determined an average
nuclear score of 80±14 in normal oral mucosa, 91±23 in light
dysplasia, 91±23 in moderate dysplasia, 93±21 in severe
dysplasia and 86±35 in carcinoma tissues.
In our study, the highest hTERT scores with the same
NCL-hTERT antibody were found in carcinoma tissue, with
an average value of 8.5±3.8, followed by squamous epithelial
tissue in the tumor center with 6.8±3.8 (Fig. 1), tumor margin
tissue with 7.4±4 and tumor distant tissue with 6.8±4 (Fig. 2).
Chen et al (50) also found cytoplasmic scores ranging in
ascending order from those found in normal mucosa up to
those for carcinoma. We did not make quantitative evaluations
of cytoplasmic staining, we observed however that there was
no or only little cytoplasmic staining with the NCL-hTERT
antibody (Ab 3).
In the study by Freier et al (51) a non-specified polyclonal
anti-hTERT antibody by Abcam was used (see our Ab 7 and
Ab 8, Table II). The authors compared immunohistochemical
results with those attained by fluorescence in situ hybridization
and were able to establish cytoplasmic and nuclear hTERT
expression (71%) on 218 squamous cell carcinomas in the
oral region which were significantly higher than that on
squamous cell carcinomas in larynx samples (35/89; 36%).
The authors concluded that higher and more frequent hTERT
expression was a suitable target for anti-neoplastic therapy.
Correlation of hTERT score values and telomerase activity in
HNSCC. None of the few immunohistochemical studies dealing
with hTERT on squamous cell carcinomas in the head and
neck has correlated its results to telomerase activity (47-51).
Gonzalez-Quevedo et al (52), who demonstrated hTERT in
the RT-PCR in various tumors, pointed to a direct correlation
between telomerase activity (determined in TRAP-ELISA)
and hTERT. This was congruent with the findings of Fujimoto
et al (53). The authors also demonstrated hTERT in diverse
cell cultures, including cell cultures from oral SCC and oral
keratinocytes, by RT-PCR and found a good correlation with
the telomerase activity determined in TRAP. In carcinoma
tissue, the telomerase activity we found by TRAP-ELISA
in HNSCC (Tables III and IV) correlated with the hTERT
expression we found by immunohistochemistry with all anti-
bodies (¯2 test: p>0.05). The lowest correlation was found
with antibody code NB 100-317 (Ab 11: ¯2 test: p=0.086). In
surgical tumor margin tissue, the hTERT scores with the
antibody EST21-A (Ab 2) and the level of telomerase activity
differ significantly: ¯2 test: p=0.038. All further hTERT scores
in the tumor margin and tumor distant tissues (Table V)
correlate in varying degrees with telomerase activity. We
ascertained in our study, as had other authors in regard to
diverse tumors (21,52,54-57), that the absence of telomerase
activity [under 150 mOD (13-15)] does not always coincide
with the absence of hTERT expression and vice versa. Shay
et al (58) did not always observe a correlation between the
levels of telomerase and those of hTERT expression, while
Etheridge et al (59) found a strong correlation between
telomerase activity and hTERT expression. Only rarely did Wu
et al (60) demonstrate hTERT with RT-PCR in telomerase-
negative tissues taken from various skin tumors.
With the antibody code 582005 (our Ab 4) hTERT scores
did not always correlate with the telomerase activity demon-
strated, a result again conforming to Yan et al (21), who more-
over also demonstrated hTERT expression in telomerase-
negative tissue. This non-correlation was also observed with
other antibodies in our study.
Correlation between hTERT score values and clinical outcome
of patients with HNSCC. We examined Kaplan-Meier curves
for a relationship between our hTERT score values for the
individual antibodies and patient outcome. As determined using
the antibodies Ab 2, Ab 3, Ab 7, Ab 10 and Ab 11, periods
without relapse were shorter, if not significantly shorter, for
patients with high hTERT expression in the carcinoma than
those for patients with lower hTERT expression. However, we
also observed the opposite, i.e., that higher hTERT expression
on the squamous epithelium in carcinoma tissue pieces was
associated with longer periods of remission (Ab 3). Between
the extended Kaplan-Meier curves there were no significant
differences. Only the comparison (in the Kaplan-Meier curves)
of hTERT expression on carcinoma in the tumor center with
the polyclonal anti-hTERT antibody code ab177 (our Ab 7,
Table II) approximated any significance. Survival times were
distinctly shorter with higher hTERT expression than with
lower hTERT expression (Fig. 6).
Pannone et al (61) found no connection between the
immunohistochemically determined hTERT and patient out-
come with oral HNSCC after surgery therapy. The only
exception to this was one high hTERT expression noted in
tumor staging I which was associated with poor prognosis.
Examining oral HNSCC patients, Chen et al (50) correlated
significantly shorter survival times and higher nuclear hTERT
expression with the antibody NCl-hTERT (clone 44F12, Ab 3,
Table II). Numerous studies on various tumors attest to a
connection between hTERT expression (determined in
immunohistochemistry or in RT-PCR) and prognosis (18-20,
48,50,54,62-64). Nor was the controversial NCL-hTERT anti-
body (48,50,63,64) the only antibody used in immunohisto-
chemical examinations. A correlation between patient outcome
and higher hTERT IRS scores emerged as well with antibody
code sc-71212 (H-231, our Ab 5) (54,62) and antibody code
582005 [our Ab 4 (20,64)]. These results are corroborated
by very few authors. Toomey et al (65) explored hTERT
expression in patients with an operable lung carcinoma using
an anti-hTERT antibody by Santa Cruz (code C20) and found
no correlation in the Kaplan-Meier curve between high hTERT
expression and patient outcome. Tabori et al (66), using our
Ab 3 in ependymomas, were able to demonstrate a significantly
shorter survival time in patients with higher hTERT expression
(p=0.05). In patients with a mamma carcinoma, hTERT as
demonstrated by Elkak et al (67) using the NCL-hTERT
antibody (our Ab 3) did not correlate in the ¯2 test with lymph
node status, grading or tumor size. Mavrommatis et al (68)
observed that nuclear hTERT (anti-hTERT code sc-7215 by
Santa Cruz) was a good and independent parameter for the
overall survival of patients with a bladder carcinoma.
Immunohistochemical hTERT proof in control tissues. In
normal cervix epithelium, Frost et al (33) showed immuno-
histochemical proof of hTERT in the basal and supra basal
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layers. Depending on the degree of dysplasia, hTERT was
also expressed in the higher epithelial layers. With the same
monoclonal antibodies (clone 4B1) Wada et al (43) demon-
strated basal and somewhat stronger parabasal hTERT in
normal vulva mucosa. In paraffin sections, Yan et al (21)
used four anti-hTERT antibodies which we had also used
(Table II): the polyclonal antibody by Oncogene (PC563; Ab 1)
which in our study was very weak; the polyclonal ab177 anti-
body (in our study Ab 7); the polyclonal Ab 2 by Calbiochem
(code 582005, in our study Ab 4) and the monoclonal NCI-L-
hTERT antibody (in our study Ab 3). The authors demon-
strated only very little hTERT expression in the basal layer
of bladder tissue. Hiyama et al (17), on the other hand, were
able to give immunohistochemical evidence in paraffin sections
of hTERT expression in a series of normal cells using the anti-
EST2 antibody (in our study Ab 2): in basal keratinocytes of
the skin, in basal cells of the endometrium and in epithelial
cells from the mamma, in lymphocytes from tonsils, spleen,
thymus, in lymphocytic infiltrates and trophoblasts from
placenta. Volpi et al (69) reported nuclear, nucleolar and
cytoplasmic proof of hTERT with a monoclonal antibody Tel
366-10 in different cell lines and in normal tissue (skin,
prostate, mamma, cervix, bladder, kidney, pancreas and colon).
Using the monoclonal NCL-hTERT, Luzar et al (49) found
the lowest hTERT expression in normal larynx epithelium
from control persons (mean hTERT index 0.17) in comparison
to increasing expression in hyperplastic tissue (0.44), in basal
hyperplasia (0.54), atypical hyperplasia (0.91), carcinoma
in situ (1.05) and in larynx carcinoma (0.96).
In the present study we investigated tissue from patients
without tumors. The tissues originated from patients of our
clinic with squamous epithelial tissue which was normal only
in part, being taken from inflamed tissue or tissue which was
hyperplastic or to varying degrees dysplastic. Independent of
the polyclonal and monoclonal antibodies used, the hTERT
expression was localized in normal squamous tissues in the
basal to parabasal layers, in dysplastic squamous epithelium
over the entire epithelium. Immunoreactive hTERT scores also
varied: Table VI and Fig. 3. In control tissues hTERT scores
were also the lowest with antibodies Ab 2 and Ab 6, as was the
case in tissues from HNSCC (Figs. 1 and 2).
Telomerase activity was significantly higher in oral control
tissues than in extraoral control tissues (p=0.023), as was the
expression of control antibodies Ki-67 (p=0.006) and CD45
(p=0.032). hTERT expression was also higher in the oral
control tissues with antibodies Ab 2 to Ab 8 than in the extra-
oral tissues, with Ab 7 significantly higher (p=0.010). In
contrast to this, hTERT scores were higher with Ab 9 to Ab 11
in extraoral tissues than in oral tissues, reaching significance
with Ab 11 (p=0.043). Comparison of the scores of all anti-
bodies shows that the scores diverged significantly between
the Ab 3 (NCL-hTERT) and the anti-nucleolin antibody
(Ab 13): p=0.013 (U test). There was a correlation between the
level of telomerase and the immunoreactive scores (¯2 test:
p>0.05).
As was the case in tumor patient tissues containing no
epithelial cells, control patient tissues containing no squamous
epithelial cells (not listed in Results) only rarely showed
nuclear marking of lymphocytic infiltration in the stroma
with the antibodies Ab 4, Ab 6 or Ab 8 to Ab 11. Endothelia
were marked predominantly with hTERT antibodies Ab 4,
Ab 8, Ab 9 to Ab 11.
Nuclear demonstration of hTERT in frozen sections and
nuclear demonstration of antibodies showing the best
nuclear hTERT staining. Eleven antibodies, Ab 1 to Ab 11
(Table II) were tested in our study for nuclear demonstration
of hTERT on frozen sections. Among them was also the
controversial NCL-hTERT antibody (23), Ab 3 of our study.
We started work with the four antibodies available to us: Ab 1
to Ab 4. The immunoreactive scores (IRS) achieved in HNSCC
with the polyclonal antibody Ab 1 (code PC563) by Oncogene/
Calbiochem were so low that it can be considered unsuitable
for frozen sections. As was the case in Yan et al (21), the
nuclear staining obtained with our Ab 1 was ambiguous, and
we abandoned this antibody.
With the other three antibodies, the two polyclonal anti-
bodies code EST21-A (Ab 2) and code 582005 (Ab 4) and the
monoclonal NCL-L-hTERT (clone 44F12, Ab 3), we worked
out the best immunohistological localization of hTERT in the
nuclei of the frozen sections. These antibodies had already
been used successfully by Hiyama et al (17), Poremba et al
(18-20), Yan et al (21) and Park et al (22) in paraffin-
embedded material (tissue, cells). To achieve nuclear staining
in frozen sections in our study, methanol-acetone fixation
followed by pretreatment in a steamer in a slightly acidic
buffer proved the most suitable method. Taylor et al (70,71)
had carried out comparisons using immunohistochemical
methods as we had between diverse antibodies on paraffin
sections without pretreating the sections and after pretreatment
in the microwave, autoclave, and steamer. Only with some
antibodies did Taylor et al find best results after pretreatment
in the steamer. Steamers have been used only rarely for frozen
sections (72) and up to now not for anti-hTERT antibodies.
We observed occasionally diffuse or a cytoplasmic staining
after pretreatment in the steamer. hTERT staining in frozen
sections without pretreatment in the steamer was successful
predominantly in cytoplasm and only in a few isolated cells
with Ab 1 to Ab 4 and the other anti-hTERT antibodies
(Table II). For determining the semiquantitative immuno-
reactive hTERT scores we included only nuclear antibody
marking. We agree with Poremba et al (20), who regarded
cytoplasmic staining as non-specific and rated it as unlabeled.
We recorded cytoplasmic staining as negative, i.e., showing
no nuclear marking.
The polyclonal anti-hTERT antibody code EST21-A (Ab 2,
Table II) is directed against 16 amino acids of the middle region
of the hTERT sequence. It produced the weakest nuclear
staining on frozen sections in our preliminary examinations.
This was confirmed on an adequate number of tissues (Figs. 1-3
and Tables III-VI). Hiyama et al (17,73-76) achieved strong
nuclear hTERT staining with this same antibody on paraffin-
embedded cells and biopsies, suggesting that EST21-A is less
effective for frozen sections. Miyazu et al (75) also demon-
strated pronounced hTERT expression on paraffin sections
from lung tumors and normal lung squamous tissue. The
EST21-A antibody actually produced significant demonstration
of hTERT in 23 patients with histopathologically normal
epithelium, and patients with higher hTERT expression in
epithelial tissue developed lung carcimomas. Similar results
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were recorded by Hashimoto et al (76) in paraffin sections of
pancreas tumors and normal pancreas tissue. Higher hTERT
expression in pancreatic epithelial tissue points to a malignant
transformation. 
We achieved particularly good nuclear and even nucleolar
marking with the monoclonal antibody NCL-L-hTERT (Ab 3),
which is directed against the amino acid sequence 173-320 of
the N-terminal domain of the hTERT sequence. This antibody
has been applied by many authors in recent years to demon-
strate hTERT. Wu et al (23) summarize the most important
work done up to 2006 but comment on the use of the NCL-L-
hTERT for immunohistochemical demonstration of hTERT.
From their spectrometric investigation of the antibody,
supplemented with findings from two-dimensional gel analysis
and immunofluorescence, they concluded that the antibody
NCL-hTERT targets nucleolin rather than hTERT.
Having acquainted ourselves with the work by Wu et al
(23), we were particularly careful in evaluating the score
values obtained with the controversial antibody. To reinforce
our findings we supplemented our study with an additional
anti-nucleolin antibody (Ab 13, Table II). As already shown
by Ohkoudo et al (77) the immunohistochemical picture after
we applied the anti-nucleolin antibody occasionally resembled
those with the anti-hTERT antibody NCL-L-hTERT (Ab 3:
Fig. 5a).
In their study, Wu et al (23) also included a polyclonal
antibody by Calbiochem (code 581400) directed against the
amino acid sequences 568-581, the central domain of the
hTERT peptide sequence. We suspect that this antibody is
comparable to the two polyclonal antibodies by Calbiochem,
Ab 4 (code 582005) and Ab 6 (code 582000) used in our study.
Ab 4 and Ab 6 are directed against an unknown immunogen in
the internal region of the hTERT sequence. In our preliminary
investigations the antibody code 582005 (Ab 4, Fig. 5b) dis-
played clear staining of the entire nucleus with simultaneous
cytoplasmic staining and non-specific background staining.
Our results with the frozen sections were comparable to those
published for paraffin sections (18-22,64,78,79). Like Yan et al
(21), we found that this pronounced cytoplasmic staining made
evaluation of immunoreactive scores difficult. By contrast, the
distinct nucleolar picture presented by the antibody NCL-L-
hTERT (Ab 3, Fig. 5a) made semiquantitative detection of
score values easier.
The values rendered with the polyclonal TERT (H-231)
antibody, code sc-7212 (Ab 5) ranged from very low to
negative. This antibody is recommended by the manufacturer
for immunofluorescence and has been reported by Wei and
Younes (62), Hoang-Vu et al (54) and Boltze et al (80) to
give good proof of hTERT in a variety of different tumors.
However, given the results we obtained, we abandoned its
further use and did not report in detail the results obtained
with it.
With the polyclonal antibody code 582000 (Ab 6, Table V)
background staining was markedly weaker than with antibody
code 582005 (Ab 4). Just as with hTERT scores with Ab 2
(code EST21-A), however, values with Ab 6 were much lower
than those with other antibodies, particularly with the antibody
Calbiochem code 582005 (Ab 4) (Figs. 1-3).
We investigated two polyclonal anti-hTERT antibodies
by Abcam (our Ab 7 = code ab177 and its successor, code
ab23699, our Ab 8, Table II). Both showed nuclear staining
(Ab 7: Fig. 5c and Ab 8: Fig. 5d). hTERT score values were
higher with the antibody code ab177 (Figs. 1-3). With the same
antibody, Yan et al (21) had obtained only cytoplasmic staining
in paraffin slides of telomerase-positive and telomerase-
negative tissues.
To validate the results of their immunohistochemical study
on giant cell tumors, Forsyth et al (81) applied the monoclonal
antibody NCL-hTERT as well as the same polyclonal anti-
hTERT antibody code 600-401-252 (Rockland) used by Wu
et al (23) (in our study Ab 9, Table II). The two antibodies
yielded similar nuclear staining of osteoclasts and mononuclear
cells, with one or more than one small-to-large aggregates in
the nucleus. Applying the same antibody, we observed nuclear
staining of carcinomas, squamous epithelial cells, endothelial
cells and occasional blood cells. Forsyth et al (81) also
observed, along with a staining of nuclear aggregates, a diffuse
distribution of nuclear staining and fine granular cytoplasmic
staining. Neither Forsyth et al (81) nor we observed any
cytoplasmic staining with the antibody NCL-hTERT (our
Ab 3). Wu et al (23, and supplementary Fig. 1 therein)
consider the polyclonal antibody by Rockland, which is
directed against the C-terminal domain of the hTERT sequence
(aa 1104-1123), to be the most important of the anti-hTERT
antibodies studied by them. Our immunohistological images
with the code 600-401-252 antibody by Rockland (Figs. 1-3
and 5e) displayed clear nuclear marking and cytoplasmic
staining. It is noteworthy that the hTERT scores were higher
in the squamous epithelial cells of extraoral control tissue
than in the oral tissues (Fig. 3).
We obtained clear nuclear marking with both of the mono-
clonal anti-hTERT antibodies by Novus Biologicals (Table II)
Ab 10 and Ab 11 (clone 2D8, code NB 100-297 and clone
2C4, code NB 100-317). In most cases the entire nucleus was
marked (see Ab 10: Fig. 5f). In our investigation with Ab 11
(code NB 100-317) the cytoplasm was also partially marked.
Both are IgM antibodies, as opposed to all other anti-hTERT
antibodies used by us, which belong to the IgG classification.
The two antibodies are directed against the entire length of the
hTERT peptide sequence (aa 1-1132). The code NB100-317
antibody was also studied by Wu et al (23). Using immuno-
fluorescence, Masutomi et al (82) detected a subcellular
localization of hTERT on mortal and immortal human cell
lines with the monoclonal anti-hTERT antibody clone 2C4
(Ab 11, Table II). The nuclear pattern with this antibody was
comparable to a polyclonal (not specified) anti-hTERT anti-
body. In addition, the authors found nucleoplasmatic staining
with this antibody, corroborating our results. Lin et al (83),
using the monoclonal anti-hTERT antibody clone 2C4 by
Abcam in mutational exclusion studies, were able to confirm
a diffuse nuclear localization with the antibody.
Using the three control antibodies Ab 12 to Ab 14 (Table II)
we also applied the steamer for the immunohistochemical
demonstration of Ki-67, nucleolin and CD45 expression. How-
ever, pretreatment of the frozen sections was not crucial for
these antibodies. Originally we used the monoclonal antibody
PCNA (proliferating cell nuclear antigen, clone PC 10, code
M0879, Dako) as a marker for proliferation instead of Ki-67,
but it labeled only cells in the S-phase, in which telomerase
and hTERT expression are at their maximum (84). The PCNA
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score values yielded by our immunohistochemical processing
were however very low, so we used Ki-67 (Ab 12) throughout
the entire study in spite of the fact that with this antibody all
cells in the cell cycle are marked. Ki-67 (score values in
Tables III-VI) had the further advantage that it allowed easy
recognition of any small carcinomatous areas on the frozen
sections.
Specificity of anti-hTERT antibodies applied. In our study the
antibody Ab 3 (NCL-L-hTERT, Table II) characteristically
showed predominantly nucleolar staining (Fig. 5a). We
extended the scope of our study with immunoabsorption tests
to determine whether Ab 3 and other anti-hTERT antibodies
indicate nucleolin. Most antibodies in our study were absorbed
with one nucleolin peptide and two hTERT peptides. Thus,
we included an anti-nucleolin antibody (Ab 13, Table II). As
a peptide control we used albumin, as had Frost et al (33).
Neither in the experiments of Frost et al nor in ours did the
albumin inhibit any of the antibodies. Frost et al (33) used their
own monoclonal antibody [clone 4B1 (46)] against hTERT
sequence aa 549-831 for the immunoabsorption and were
able to completely block the diluted antibody with 375 ng
hTERT protein. In the immunoabsorption of a polyclonal
anti-prostaglandin receptor antibody to determine antibody
specificity, Nakamura et al (85) used 16 times more peptide
than antibody and achieved the same effect as had Frost et al
(33). Blocking tests have also been used to determine anti-
body specificity. Klinck et al (86) investigated 4 monoclonal
antibodies on pancreas sections using immunofluorescent
techniques before and after peptide blocking and were thus
able to characterize the antibodies.
To demonstrate successful absorption, we, like Frost et al
(33), subjected the antibodies to immunohistochemical
investigation with and without absorption. We increased the
number of sections included to minimize subjectivity in score
evaluation. This in turn required substantial volumes of anti-
body, and the amounts of peptide we used achieved in fact only
partial antibody absorption (Fig. 4). The fact that antibody
Ab 8 was only partially blocked by their homologous
peptides ab23699 indicates that the amounts of peptide used
were insufficient. It is also conceivable that peptides and
antibodies were only partially homologous.
Absorption of the antibodies by the peptide EST-21-P
(homologous to Ab 2 in our study) was low: Ab 10 (50%),
Ab 9 (33%), Ab 3 (30%), Ab 7 (28%), Ab 4 (26%) and Ab 8
(no absorption) (Fig. 4). Ab 11 (NB 100-317) absorption with
EST21-P was not tested.
The polyclonal antibody ab23699 (Ab 8) was 59% absorbed
(score after absorption 41%) by the homologous peptide
ab24029. The percentages for other antibodies absorbed by
this peptide were lower: Ab 11 (56%), Ab 3 (46%), Ab 7 (35%),
Ab 10 (27%), Ab 9 (24%) and Ab 4 (21%). Only 8% of the
anti-nucleolin antibody (Ab 13, Table II) was absorbed by
the hTERT peptide ab24029 (score after absorption 92%).
The homologous nucleolin peptide ab25315 absorbed 100%
of the anti-nucleolin antibody (Ab 13, Table II) but did not in
any test block the antibodies Ab 4, Ab 9, Ab 10 or Ab 11.
The other antibodies were absorbed by the nucleolin peptide
as follows: Ab 8 (60%), Ab 3 (21%), Ab 7 (17%). Only 21%
of the anti-hTERT antibody NCL-L-hTERT, which
according to Wu et al (23) is an anti-nucleolin antibody, was
absorbed by the nucleolin peptide, but 30% and 46% of the
same antibody was also absorbed respectively by the two
hTERT peptides EST21-P and ab24029. Although our
immunoabsorption results are not unambiguous, they never-
theless support the view that not only nucleolin is demon-
strated by the antibody NCL-L-hTERT. We may conclude
that the antibody Ab 3 is not exclusively directed against
nucleolin, but that the antibodies Ab 4, Ab 9, Ab 10 and Ab 11
are not directed against nucleolin (Fig. 4). While the polyclonal
antibody Ab 4 is directed against the (unspecified) internal
hTERT region and the polyclonal Ab 9 against the C terminal
domain (aa 1104-1123), the monoclonal antibodies Ab 10 and
Ab 11 are directed against the entire length of the hTERT
peptide sequence.
Proof of hTERT and telomerase function. With anti-hTERT
antibodies 2-4 and 6-11 we were able to demonstrate nuclear
hTERT expression of varying intensity (Figs. 1-3 and 5),
albeit directed at different hTERT domains. Whether this test
is related to a function of telomerase can not be determined
on the basis of the immunohistochemical scores. From the
studies by Etheridge et al (59) and Wong et al (87) it is
known that temporary hTERT expression is concentrated in
the nucleoplasm of human cells, particularly in the nucleolus.
Zhu et al (88) confirmed this location to Cajal bodies with
fluorescent in situ hybridization in HeLa cells and in some
other carcinoma cell lines. Yang et al (89) found through
fluorescence tagging experiments that the nucleolar localization
of hTERT depends on the N-terminus (aa 1-15) of hTERT
(23) and is associated with telomerase function. This
localization is cell cycle dependent. Lin et al (83) were able
to show by hTERT mutation of residues 254 and 265 in
HeLa cells that the nucleolar binding of hTERT and
telomerase function are not identical and that mutational
inactivation of hTERT C-terminals 965-981 maintains telo-
merase function despite suspension of nucleolar binding in
human and mouse cell lines (90).
The third antibody used in this study (NCL hTERT,
Table II), with its typical nucleolar marking (Fig. 5a), is
directed against an N terminal hTERT sequence. Lam et al
(63) verified with the NCL-L-hTERT antibody that telomerase
and nucleolin interact with one another and display the same
intracellular distribution. They concluded that despite the
criticism of Wu et al (23) telomerase activity can also be
demonstrated with this antibody. Nucleolin is a nucleolar
phosphoprotein (91) used with nucleolin-specific antibodies
to identify nucleoli (92). Khurts et al (91) revealed that
nucleolin interacts with telomerase and changes its sub-
cellular localization. In this process it can bind with hTERT,
with significant consequences for its nucleolar localization.
Cells which may be responsible for telomerase activity outside
the carcinoma (tumor margin tissue, tumor distant tissue, and
control tissue). Mao et al (10,93) demonstrated telomerase in
carcinoma-free tumor margins in head and neck tumors and
addressed the question of whether the presence of telomerase
activation occurs by lymphocytic infiltration in the tissue or
whether it was an expression of field cancerization (1,2) in
the region surrounding the tumor. In previous examinations we
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had demonstrated a limited correlation between telomerase
activity and lymphocyte infiltration in tumor margin tissues
(13,14,94,95).
Hiyama et al (94), Counter et al (96) and Broccoli et al
(97) demonstrated a low level of telomerase activity in
hematogenic cells which was higher in stimulated lympho-
cytes (94,97,98). Shay and Wright (99) observed telomerase
activity of the mononuclear cells in 124 blood samples the
intensity of which varied with the number of cells used.
Detectable lymphocytic infiltration has been described in
HNSCC tumor margin tissue (100-103). We applied a mono-
clonal CD45 antibody (Ab 14, Table II) to evaluate lympho-
cytic-monocytic infiltrates. Statistical comparison revealed
a significant variance between the CD45 scores and the
extremely low hTERT score values with antibodies Ab 2 and
Ab 6 in the tumor margin of squamous cell carcinoma and
with antibody Ab 2 in tumor distant tissue of SCC patients.
In the tumor margin tissue there was no significant difference
between hTERT scores revealed by clearly marked antibodies
(Ab 3, Ab 4 and Ab 7) and the CD45 scores. The CD45
scores were significantly higher in oral control tissues than in
extraoral control tissues (p=0.032) (Table VI). In earlier studies
we rarely observed a correlation between telomerase levels in
the tumor margin and tumor distant tissues of HNSCC and
the lymphocytic infiltrates detected by histopathology (13,14).
We demonstrated only isolated hTERT marked cells in the
stroma of these tissues.
To check for field cancerization (1,2) in tumor margin
tissue which had been histopathologically characterized as
carcinoma-free, we investigated the hTERT scores of squamous
epithelial cells in the tissues (Fig. 2 and Table V) with the
antibodies Ab 2 to Ab 4, Ab 6 and Ab 7. Kim et al had
identified telomerase activity in 38% (16), Mao et al in 43%
(10), Hohaus et al in 76% (104), Patel et al in 74% (11) and
Yajima et al in 19.4% (93) of carcinoma-free tumor margin
tissues some of which were dysplastic. In the present study
we found positive telomerase values (13-15) in 52% of the
tumor margin and 30% of the tumor distant tissues of patients
with squamous cell carcinomas.
Up to now only few tumor margin tissues from head and
neck tumors have been inspected for hTERT. Luzar et al (49)
compared immunohistochemical proof of hTERT detected
with the NCL- hTERT antibody (our Ab 3) with RT-PCR
results in tumor margin tissues from larynx carcinomas
showing varying degrees of hyperplasia. Both methods showed
that increasing hTERT expression is an early event in larynx
carcinogenesis. This concurs with the results of Eissa et al
(105), who with real-time PCR and fluorescence cytophoto-
metry found lower hTERT levels in larynx tumor margin tissue
than in the carcinomas.
The present investigations showed that in addition to the
lymphocytic infiltrates in carcinoma-free tumor margin tissues,
hTERT was also expressed in squamous epithelial cells
distributed in the basal but also in the suprabasal layer and
throughout the entire squamous epithelium of the same tissues.
hTERT expression was highest when the antibodies Ab 3, Ab 4
and Ab 7 (Table II) were applied (Fig. 2, Table IV). ¯2 test
registered a correlation between hTERT scores and telo-
merase activation. The result emerging from these investi-
gations was that lymphocytic infiltration and especially field
cancerization of the squamous epithelium in carcinoma-free
resection margins are the cause of telomerase activity in
these tissues. Whether hTERT is a suitable target for
adjuvant therapy of head and neck tumors, as is suggested
by Freier et al (51), cannot be determined in our experiments
unambiguously.
For our study of hTERT-detection in the squamous
epithelia of carcinoma free tumor margins and tumor distant
tissues (Fig. 2) we applied antibodies Ab 2, Ab 3, Ab 4, Ab 6
and Ab 7. Ab 3 (code NCL-hTERT), Ab 4 (code 582005) and
Ab 7 (code ab177) were particularly suited for causing sensitive
hTERT reaction in field cancerization of these tissues or
for demonstrating disseminated individual carcinoma cells
(minimal residual disease/MRD). Ab 8 to Ab 11 were not
applied to tumor margin and tumor distant tissues, but in
immunohistochemical testing exhibited intense nuclear and/
or nucleolar marking in carcinoma (Table III, Fig. 1) and in the
squamous epithelium of the HNSCC tumor center (Table IV,
Fig. 1). That is why Ab 8 (code ab23699), Ab 9 (code 600-
401-252), Ab 10 (code NB 100-297) and Ab 11 (code NB
100-317) are also well suited for the detection of hTERT
expression and field cancerization. Considering the evidence
given by Wu et al (23,106) and our results for immuno-
absorption, the following conclusion can be drawn: antibodies
Ab 4 and Ab 9 to Ab 11 are particularly well suited for
identifying field cancerization and for proof of MRD. We were
unable to demonstrate absorption of these antibodies with the
nucleolin peptide ab25315 (Fig. 4). If necessary Ab 3 is also
useful for demonstrating both field cancerization and MRD.
In the Fisher exact test a correlation appears between the
level of hTERT scores for these 5 antibodies and telomerase
activity (Table III): p-values between 0.086 (Ab 11) and 0.752
(Ab 3).
We agree with Lantuejoul et al (107), however, that it is
important to develop new anti-hTERT antibodies against
proteins or peptides which do not react or cross-react with
nucleolin. Manufacturers of the NCL-L-hTERT antibody
should feel prompted by the critical publications of Wu et al
to re-examine the antigen specificity of their antibody. Xiao
et al (106) conclude from their studies on culture cells and
tissues fixated in formalin that chicken IgG antibodies can
have definite advantages over the commonly used mammal IgG
antibodies and exhibit less non-specific staining. Irrespective of
the afore-mentioned objections, many authors continue to use
the monoclonal NCL-L-hTERT for immunohistochemical
proof of hTERT (63,66,107-112).
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